Advitech Announces New Efficacy Results for Dermylex and Compliance with FDA Regulations on Claims
QUEBEC CITY, Sept. 12 /CNW Telbec/ - Advitech Inc. ("Advitech"
or the "Corporation") (TSX Venture Exchange: AVI) announced today
that a post-marketing study conducted on patients suffering from
psoriasis shows that the use of Dermylex(TM) may benefit patients
already using topical corticosteroids. Using Dermylex(TM) with
topical corticosteroids may create a synergistic effect and improve
overall treatment efficacy results. Therefore, Dermylex(TM) might
act as an adjuvant to topical corticosteroids.
"This new data provides Advitech and its commercial partners with
important information on treatment strategies and alternatives.
Adding Dermylex(TM) to a topical corticosteroid treatment appears
to reduce psoriasis severity," stated Dr. Christina Juneau,
Advitech's Vice-President of Research and Development. "Advitech
will continue to gather and monitor additional data and results
from this post-marketing study in order to develop therapeutic
strategies for Dermylex(TM) users."
These observations arise from a study by Advitech in which
Dermylex(TM) users were invited to provide their own evaluation and
comment on the results obtained with Dermylex(TM) whether taken
alone or part of a concomitant treatment for psoriasis. In the
questionnaire, psoriasis severity was quantified by means of an
intensity scale.
Advitech Receives Confirmation from FDA That Dermylex.Claims
Meet U.s Regulations
Advitech had submitted to the U.S. Food and Drug Administration
(FDA), in June of this year, four different structure/function
claims in relation to Dermylex(TM) and recently received
confirmation by FDA's Division of Dietary Supplement Programs that
all four claims are acceptable under the agency's regulations.
These claims will be used for labeling purpose in the
commercialization of Dermylex(TM) by Advitech's partner in the U.S
market. "Regulations applicable to the U.S market are strict as
they relate to the labeling of products like Dermylex(TM). This
confirmation from the FDA is important for Advitech and its
marketing partners as it will help position Dermylex(TM) in this
strategic market," added Dr. Juneau.
About Advitech Inc. http://www.advitech.com
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of Immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease.
About Dermylex(TM) http://www.dermylex.com
Dermylex(TM), developed by Advitech, is an oral natural health product formulated to improve mild-to-moderate psoriasis symptoms. Two clinical trials, one of them a multi-center, double-blind, placebo-controlled trial with 84 patients for 112 days, clinically proved the efficacy and safety of Dermylex(TM) for that type of psoriasis. Dermylex(TM) is currently available in Canada and will soon be available in the U.S. (as BioDerm), and in France and Belgium (as Psopax).
This press release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
Actual results could differ materially from those projected herein.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
%SEDAR: 00021006EF
-30-
/For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,
info@advitech.com,
http://www.advitech.com; Serge
Comeau, Investor's relations, (514) 862-4160, s.comeau@advitech.com
Posted: September 2007
